Eris Lifesciences Sells Entire Stake In Its Subsidiaries For Rs 861.9 Crore
Eris Lifesciences Ltd. has sold its entire stake in two of its subsidiaries to Eris Therapeutics Ltd. for Rs 861.9 crore.
The company is expected to complete the stake sale in Eris Oaknet Healthcare Pvt. and Aprica Healthcare Ltd. by March 31, according to an exchange on Thursday.
Eris Lifesciences reported an 18.61% year-on-year fall in consolidated net profit to Rs 83.63 crore for the third quarter of fiscal 2025, despite a 49.61% increase in revenue from operations to Rs 727.45 crore during the same period.
The fall in net profit can be attributed in part to a significant increase in finance costs, which rose by 215% to Rs 57.17 crore from Rs 18.12 crore in the same quarter of fiscal 2024.
Sequentially, revenue from operations decreased by 1.85%, and profit declined by 8.69%.
Shares of Eris Lifesciences closed 3% higher at Rs 1,269.60 apiece on the NSE, compared to a 0.93% increase in the benchmark Nifty 50. The stock has fallen 41.87% in the last 12 months.
Out of 10 analysts tracking the company, nine suggest 'buy' and one recommends 'hold,' according to Bloomberg data. The average of 12-month analysts' price targets implies a potential upside of 18.2%.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
